Company news
Fulcrum Therapeutics, Inc. news in 2021
Fulcrum Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data
December 5, 2021
Fulcrum Therapeutics® Appoints Sonja L. Banks to its Board of Directors
November 16, 2021
Fulcrum Therapeutics® Reports Recent Business Highlights and Third Quarter 2021 Financial Results
November 3, 2021
Fulcrum Therapeutics™ to Participate in Upcoming November Investor Conferences
November 2, 2021
Fulcrum Therapeutics™ to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Thursday, November 4, 2021 at 8: 00 a.m. ET
October 27, 2021
Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2021
Fulcrum Therapeutics™ Announces Multiple Presentations During the Virtual Congress of the World Muscle Society
September 19, 2021
Fulcrum Therapeutics™ Appoints Mel Hayes as Chief Commercial Officer
September 7, 2021
Fulcrum Therapeutics™ to Participate in Upcoming Investor Conferences
September 1, 2021
Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
August 15, 2021
Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock
August 10, 2021
Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
August 9, 2021
Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease
August 9, 2021
Fulcrum Therapeutics to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Tuesday, August 10, 2021 at 8: 00 a.m. ET
August 3, 2021
Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Demonstrating Slowed Disease Progression and Improved Function
June 23, 2021
Fulcrum Therapeutics Announces Multiple Presentations at the 28th Annual FSHD Society International Research Congress (IRC)
June 20, 2021
Fulcrum Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to Losmapimod for the Potential Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
May 11, 2021
Fulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference
May 6, 2021
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
May 5, 2021
Fulcrum Therapeutics Appoints Christopher Morabito, M.D. as Chief Medical Officer
May 5, 2021
Fulcrum Therapeutics to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, May 6, 2021 at 8: 00 a.m. ET
April 28, 2021
Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual Conference
April 8, 2021
Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development
March 23, 2021
Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference
March 17, 2021
Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
March 3, 2021
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8: 00 a.m. ET
February 25, 2021
Fulcrum Therapeutics Recognizes Rare Disease Day 2021
February 25, 2021
Fulcrum Therapeutics to Participate in Upcoming Investor Conferences
February 18, 2021
Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
January 21, 2021
Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer
January 18, 2021
Fulcrum Therapeutics to Participate in the H.C. Wainwright BioConnect 2021 Conference
January 5, 2021
Calls in 2021
- Fulcrum Therapeutics (NASDAQ:FULC) Q3 2021 Earnings Call
Nov 4, 2021
Transcript - Fulcrum Therapeutics (NASDAQ:FULC) Q2 2021 Earnings Call
Aug 10, 2021
Transcript - Fulcrum Therapeutics (NASDAQ:FULC) Q1 2021 Earnings Call
May 6, 2021
Transcript - Fulcrum Therapeutics (NASDAQ:FULC) Q4 2020 Earnings Call
Mar 4, 2021
Transcript
Decks in 2021
- Technical Presentation (July 2021)
Technical · 53 slides · Jul 14, 2021